Context Since 1994, the US Public Health Service (PHS) has recommended routine, voluntary prenatal human immunodeficiency virus (HIV) testing and zidovudine therapy to reduce perinatal HIV transmission.
Objective To describe trends in incidence of perinatal AIDS and factors contributing to these trends, particularly the effect of PHS perinatal HIV recommendations.
Design, Setting, and Participants Analysis of nationwide AIDS surveillance data and data from HIV-reporting states through June 1998.
Main Outcome Measures Trends in AIDS by year of diagnosis, incidence rates of AIDS and Pneumocystis carinii pneumonia (PCP) among infants younger than 1 year from US natality data for birth cohorts 1988 to 1996 ; expected number of infants with AIDS from national serosurvey data ; and zidovudine use data from selected HIV-reporting states.
Results Perinatal AIDS cases peaked in 1992 and then declined 67% from 1992 through 1997, including an 80% decline in infants and a 66% decline in children aged 1 to 5 years.
Rates of AIDS among infants (per 100000 births) declined 69%, from 8.9 in 1992 to 2.8 in 1996 compared with a 17% decline in births to HIV-infected women from 1992 (n=6990) to 1995 (n=5797).
Among infants, PCP rates per 100 000 declined 67% (from 4.5 in 1992 to 1.5 in 1996), similar to the decline in other AIDS conditions. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Virus immunodéficience humaine, Lentivirus, Retroviridae, Virus, Transmission verticale, Périnatal, Enfant, Homme, Incidence, Zidovudine, Antiviral, Inhibiteur enzyme, RNA-directed DNA polymerase, Nucleotidyltransferases, Transferases, Enzyme, Chimiothérapie, Traitement, Chimioprophylaxie, Prévention, Femelle, Gestation, Etats Unis, Amérique du Nord, Amérique, Prénatal, Pyrimidine nucléoside, Didésoxynucléoside, Immunopathologie, Immunodéficit, Gestation pathologie
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Human immunodeficiency virus, Lentivirus, Retroviridae, Virus, Vertical transmission, Perinatal, Child, Human, Incidence, Zidovudine, Antiviral, Enzyme inhibitor, RNA-directed DNA polymerase, Nucleotidyltransferases, Transferases, Enzyme, Chemotherapy, Treatment, Chemoprophylaxis, Prevention, Female, Pregnancy, United States, North America, America, Prenatal, Pyrimidine nucleoside, Dideoxynucleoside, Immunopathology, Immune deficiency, Pregnancy disorders
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0436477
Code Inist : 002B05C02D. Création : 22/03/2000.